Literature DB >> 1696867

Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis.

Y Deguchi1, N Shibata, S Kishimoto.   

Abstract

The expression of tumour necrosis factor-alpha (TNF-alpha) gene in peripheral blood mononuclear cells from patients with systemic vasculitis, periarteritis nodosa and Wegener's granulomatosis, has been studied by RNA dot blot and Northern blot assays. We further examined the transcriptional level of TNF-alpha gene in peripheral blood mononuclear cells from these patients by performing nuclear run on transcription assay. We demonstrate enhanced TNF-alpha gene expression in mononuclear cells from these patients compared with healthy subjects and patients with bronchial asthma. These findings suggest that the enhanced transcription of TNF-alpha gene in peripheral blood mononuclear cells from patients with systemic vasculitis may be involved in the pathophysiology/pathogenesis of these diseases by cytokine dysregulation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696867      PMCID: PMC1535064          DOI: 10.1111/j.1365-2249.1990.tb03336.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  9 in total

1.  The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations.

Authors:  A S Fauci; B Haynes; P Katz
Journal:  Ann Intern Med       Date:  1978-11       Impact factor: 25.391

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation.

Authors:  J C Reed; Y Tsujimoto; J D Alpers; C M Croce; P C Nowell
Journal:  Science       Date:  1987-06-05       Impact factor: 47.728

Review 4.  Cachectin: more than a tumor necrosis factor.

Authors:  B Beutler; A Cerami
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

5.  Shock and tissue injury induced by recombinant human cachectin.

Authors:  K J Tracey; B Beutler; S F Lowry; J Merryweather; S Wolpe; I W Milsark; R J Hariri; T J Fahey; A Zentella; J D Albert
Journal:  Science       Date:  1986-10-24       Impact factor: 47.728

6.  Protooncogene expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus as an indicator of the disease activity.

Authors:  Y Deguchi; H Hara; S Negoro; T Kakunaga; S Kishimoto
Journal:  Clin Immunol Immunopathol       Date:  1987-12

7.  Effect of lymphotoxin and tumor necrosis factor on endothelial and connective tissue cell growth and function.

Authors:  M B Kahaleh; E A Smith; Y Soma; E C LeRoy
Journal:  Clin Immunol Immunopathol       Date:  1988-11

8.  The localization of circulating immune complexes in experimental serum sickness. The role of vasoactive amines and hydrodynamic forces.

Authors:  W T Kniker; C G Cochrane
Journal:  J Exp Med       Date:  1968-01-01       Impact factor: 14.307

9.  Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.

Authors:  K J Tracey; H Wei; K R Manogue; Y Fong; D G Hesse; H T Nguyen; G C Kuo; B Beutler; R S Cotran; A Cerami
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

  9 in total
  19 in total

Review 1.  Rare diseases.3: Wegener's granulomatosis.

Authors:  C A Langford; G S Hoffman
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

2.  Elevated monocytic IL-12 and TNF-alpha production in Wegener's granulomatosis is normalized by cyclophosphamide and corticosteroid therapy.

Authors:  P Lamprecht; G Kumanovics; A Mueller; E Csernok; A Komocsi; A Trabandt; W L Gross; A Schnabel
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

Review 3.  Role of proteinase 3 in activation of endothelium.

Authors:  M E Taekema-Roelvink; C van Kooten; C A Verburgh; M R Daha
Journal:  Springer Semin Immunopathol       Date:  2001

Review 4.  Assessment of disease activity in systemic vasculitis.

Authors:  W Y Tse; P Cockwell; C O Savage
Journal:  Postgrad Med J       Date:  1998-01       Impact factor: 2.401

Review 5.  Infliximab for the treatment of refractory polyarteritis nodosa.

Authors:  Shira Ginsberg; Itzhak Rosner; Gleb Slobodin; Michael Rozenbaum; Lisa Kaly; Nizar Jiries; Nina Boulman; Abid Awisat; Haya Hussein; Irina Novofastovski; Amal Silawy; Doron Rimar
Journal:  Clin Rheumatol       Date:  2019-04-10       Impact factor: 2.980

Review 6.  Pharmacological therapy for Wegener's granulomatosis.

Authors:  Eric S White; Joseph P Lynch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 7.  Mechanisms of endothelial cell injury in vasculitis.

Authors:  A A Pall; C O Savage
Journal:  Springer Semin Immunopathol       Date:  1994

8.  Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells.

Authors:  C O Savage; B E Pottinger; G Gaskin; C D Pusey; J D Pearson
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

9.  Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass.

Authors:  M Holland; P Hewins; M Goodall; D Adu; R Jefferis; C O S Savage
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

Review 10.  ANCA and associated diseases: immunodiagnostic and pathogenetic aspects.

Authors:  W L Gross; W H Schmitt; E Csernok
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.